{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:08:46Z","timestamp":1792829326986,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish Society of Cardiology"},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite its low diagnostic yield, endomyocardial biopsy (EMB) remains the gold standard for establishing a definitive diagnosis in many cardiomyopathies. We developed and validated a machine-learning\u2013based score to predict the likelihood of diagnostic EMB using non-invasive data. We retrospectively analyzed 775 heart failure patients who underwent EMB. A random forest algorithm was selected for score development based on superior discriminative performance. The model was externally validated in an independent cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009171). The study population was predominantly male (72.1%), with half of the patients in NYHA class III\u2013IV. EMB yielded a definitive diagnosis in 19.9% of cases, most commonly amyloidosis (50%). A predictive score (0-100 range) was derived from key non-invasive predictors. Right ventricular late gadolinium enhancement (LGE) on cardiac magnetic resonance emerged as the strongest predictor, followed by left ventricular and atrial LGE, NTproBNP levels, and renal function. The model demonstrated excellent discrimination, with an area under the curve of 0.92 (95% CI\u2009=\u20090.89\u20130.96) in cross-validation and 0.91 (95% CI\u2009=\u20090.86\u20130.98) in the testing set, with consistent performance on external validation (AUC 0.82, 95% CI\u2009=\u20090.76\u20130.89). This machine-learning-based score may provide a non-invasive tool to support EMB decision-making in clinical practice.\n                  <\/jats:p>","DOI":"10.1038\/s41746-026-02421-y","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:54:56Z","timestamp":1770674096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Derivation and validation of a machine learning-driven score to predict the diagnostic yield of endomyocardial biopsy"],"prefix":"10.1038","volume":"9","author":[{"given":"Christian","family":"Basile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Polte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Entela","family":"Bollano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Rawshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Oldfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Erik","family":"Bartfay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hjalmarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bj\u00f6rkenstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cannat\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pedrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristjan","family":"Karason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2421_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"2421_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1536\/ihj.3.537","volume":"3","author":"S Sakakibara","year":"1962","unstructured":"Sakakibara, S. & Konno, S. Endomyocardial biopsy. Jpn Heart J. 3, 537\u2013543 (1962).","journal-title":"Jpn Heart J."},{"key":"2421_CR3","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 44, 3503\u20133626 (2023).","journal-title":"Eur. Heart J."},{"key":"2421_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/ejhf.2380","volume":"23","author":"G Sinagra","year":"2021","unstructured":"Sinagra, G., Porcari, A., Fabris, E. & Merlo, M. Standardizing the role of endomyocardial biopsy in current clinical practice worldwide. Eur. J. Heart Fail 23, 1995\u20131998 (2021).","journal-title":"Eur. J. Heart Fail"},{"key":"2421_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-022-10247-5","volume":"28","author":"A Porcari","year":"2023","unstructured":"Porcari, A. et al. Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Fail Rev. 28, 123\u2013135 (2023).","journal-title":"Heart Fail Rev."},{"key":"2421_CR6","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1002\/ehf2.13006","volume":"7","author":"S Gobel","year":"2020","unstructured":"Gobel, S. et al. Safety of transradial and transfemoral left ventricular compared with transfemoral right ventricular endomyocardial biopsy. ESC Heart Fail 7, 4015\u20134023 (2020).","journal-title":"ESC Heart Fail"},{"key":"2421_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2459\/JCM.0000000000001162","volume":"22","author":"G Peretto","year":"2021","unstructured":"Peretto, G. et al. Right ventricular endomyocardial biopsy in patients with cardiac magnetic resonance showing left ventricular myocarditis. J. Cardiovasc. Med. (Hagerstown) 22, 560\u2013566 (2021).","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"2421_CR8","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1093\/eurheartj\/ehm456","volume":"28","author":"LT Cooper","year":"2007","unstructured":"Cooper, L. T. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur. Heart J. 28, 3076\u20133093 (2007).","journal-title":"Eur. Heart J."},{"key":"2421_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCHEARTFAILURE.112.000087","volume":"6","author":"MK Bennett","year":"2013","unstructured":"Bennett, M. K. et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ. Heart Fail 6, 676\u2013684 (2013).","journal-title":"Circ. Heart Fail"},{"key":"2421_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01169-y","volume":"13","author":"Y Marquet","year":"2023","unstructured":"Marquet, Y. et al. Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support. Ann. Intensive Care 13, 78 (2023).","journal-title":"Ann. Intensive Care"},{"key":"2421_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00005792-199907000-00005","volume":"78","author":"GM Felker","year":"1999","unstructured":"Felker, G. M. et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltim.) 78, 270\u2013283 (1999).","journal-title":"Medicine (Baltim.)"},{"key":"2421_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008387","volume":"14","author":"RMA van der Boon","year":"2021","unstructured":"van der Boon, R. M. A. et al. Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. Circ. Heart Fail 14, e008387 (2021).","journal-title":"Circ. Heart Fail"},{"key":"2421_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn, V. S. et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail 8, 712\u2013724 (2020).","journal-title":"JACC Heart Fail"},{"key":"2421_CR14","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/eurheartj\/ehae169","volume":"45","author":"ALP Caforio","year":"2024","unstructured":"Caforio, A. L. P. et al. Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry. Eur. Heart J. 45, 2548\u20132569 (2024).","journal-title":"Eur. Heart J."},{"key":"2421_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcmg.2014.09.020","volume":"8","author":"S Kuruvilla","year":"2015","unstructured":"Kuruvilla, S. et al. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc. Imaging 8, 172\u2013180 (2015).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2421_CR16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","volume":"26","author":"H Mahrholdt","year":"2005","unstructured":"Mahrholdt, H., Wagner, A., Judd, R. M., Sechtem, U. & Kim, R. J. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur. Heart J. 26, 1461\u20131474 (2005).","journal-title":"Eur. Heart J."},{"key":"2421_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/CIRCIMAGING.113.001144","volume":"7","author":"S Kuruvilla","year":"2014","unstructured":"Kuruvilla, S. et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ. Cardiovasc. Imaging 7, 250\u2013258 (2014).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"2421_CR18","doi-asserted-by":"publisher","first-page":"euab116.032","DOI":"10.1093\/europace\/euab116.032","volume":"23","author":"A Castelo","year":"2021","unstructured":"Castelo, A. et al. Late gadolinium enhancement as a predictor of arrhythmias in patients with hypertrophic cardiomyopathy. EP Europace 23, euab116.032 (2021).","journal-title":"EP Europace"},{"key":"2421_CR19","doi-asserted-by":"publisher","first-page":"ehad655.176","DOI":"10.1093\/eurheartj\/ehad655.176","volume":"44","author":"T Goncalves","year":"2023","unstructured":"Goncalves, T. et al. Prognostic impact of the extent, location, and pattern of late gadolinium enhancement in dilated cardiomyopathy. European Heart J. 44, ehad655.176 (2023).","journal-title":"European Heart J."},{"key":"2421_CR20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","volume":"118","author":"M Holzmann","year":"2008","unstructured":"Holzmann, M. et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118, 1722\u20131728 (2008).","journal-title":"Circulation"},{"key":"2421_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jcmg.2011.11.022","volume":"5","author":"P Lurz","year":"2012","unstructured":"Lurz, P. et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc. Imaging 5, 513\u2013524 (2012).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2421_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12968-017-0357-3","volume":"19","author":"C Unterberg-Buchwald","year":"2017","unstructured":"Unterberg-Buchwald, C. et al. Targeted endomyocardial biopsy guided by real-time cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson 19, 45 (2017).","journal-title":"J. Cardiovasc. Magn. Reson"},{"key":"2421_CR23","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.jacc.2018.03.521","volume":"71","author":"KW Johnson","year":"2018","unstructured":"Johnson, K. W. et al. Artificial Intelligence in Cardiology. J. Am. Coll. Cardiol. 71, 2668\u20132679 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2421_CR24","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/heartjnl-2017-311198","volume":"104","author":"K Shameer","year":"2018","unstructured":"Shameer, K., Johnson, K. W., Glicksberg, B. S., Dudley, J. T. & Sengupta, P. P. Machine learning in cardiovascular medicine: are we there yet? Heart 104, 1156 (2018).","journal-title":"Heart"},{"key":"2421_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029481","volume":"12","author":"E Bobbio","year":"2023","unstructured":"Bobbio, E. et al. Clinical Outcomes and Predictors of Long-Term Survival in Patients With and Without Previously Known Extracardiac Sarcoidosis Using Machine Learning: A Swedish Multicenter Study. J. Am. Heart Assoc. 12, e029481 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"2421_CR26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana, M. et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 132, 1570\u20131579 (2015).","journal-title":"Circulation"},{"key":"2421_CR27","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"2421_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 16, 233\u2013270 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"2421_CR29","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jez232","volume":"20","author":"SE Petersen","year":"2019","unstructured":"Petersen, S. E., Khanji, M. Y., Plein, S., Lancellotti, P. & Bucciarelli-Ducci, C. European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. Eur. Heart J. Cardiovasc. Imaging 20, 1321\u20131331 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"2421_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger, J. et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update : Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J. Cardiovasc. Magn. Reson 22, 19 (2020).","journal-title":"J. Cardiovasc. Magn. Reson"},{"key":"2421_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-14-17","volume":"14","author":"RA Noureldin","year":"2012","unstructured":"Noureldin, R. A. et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 14, 12 (2012).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"2421_CR32","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.2190","volume":"23","author":"PM Seferovi\u0107","year":"2021","unstructured":"Seferovi\u0107, P. M. et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur. J. Heart Fail 23, 854\u2013871 (2021).","journal-title":"Eur. J. Heart Fail"},{"key":"2421_CR33","doi-asserted-by":"publisher","first-page":"e21798","DOI":"10.2196\/21798","volume":"8","author":"F Xie","year":"2020","unstructured":"Xie, F., Chakraborty, B., Ong, M. E. H., Goldstein, B. A. & Liu, N. AutoScore: A Machine Learning-Based Automatic Clinical Score Generator and Its Application to Mortality Prediction Using Electronic Health Records. JMIR Med. Inf. 8, e21798 (2020).","journal-title":"JMIR Med. Inf."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02421-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:30Z","timestamp":1773770850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1038\/s41746-026-02421-y","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. reports a clinical training grant from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and a training grant for research in foreign institutions from the Italian Society of Cardiology (SIC). C.L.P. has no conflict of interest to declare. P.G. has no conflicts of interest to declare. E.B. has no conflicts of interest to declare. A.R. has no conflict of interest to declare. A.O. has no conflict of interest to declare. C.L. has no conflict of interest to declare. S.B. has no conflict of interest to declare. P.D. has no conflict of interest to declare. C.H. reports personal lecture fees from Janssen, Johnson & Johnson and has been involved in research advisory boards for AOP Health\/OrphaCare and is also a receiver of the grant from Merck Sharp & Dohme LLC. M.B. has no conflict of interest to declare. EG has no conflict of interest to declare. A.C. is supported by the British Heart Foundation (FS\/CRTF\/21\/24175). P.P. has no conflict of interest to declare. A.G. has no conflict of interest to declare. G.S. reports grants from Vifor Pharma, Novartis, Boehringer Ingelheim, Boston Scientific, AstraZeneca, Pharmacosmos, Merck, Bayer, Cytokinetics, and Servier, consulting fees from TEVA, AstraZeneca, Medical Education Global Solutions, Atheneum, Genesis, CSL Vifor, Servier, and Translational Medicine Academy Foundation (TMA), speaker fees from Novartis, Roche, Cytokinetics, Hikma, Medtronic, Pharmacosmos, AstraZeneca, Menarini, Vifor Pharma, INTAS, and GETZ, support for attending meetings from Boehringer Ingelheim and Servier, and fees for participating on data safety monitoring board or advisory board outside the present work from AstraZeneca, Edwards LifeScience, Uppsala Clinical Research Center (UCR), CSL Vifor, Servier, Abbott, Cytokinetics. A.P.M. reports fees for participating in study committees outside the present work from AstraZeneca, Bayern, Novartis and Sanofi. K.K. has no conflict of interest to declare. E.B. has no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}